Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma
Table 5
Results of scenario analyses under different simulation time horizons.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Results of scenario analyses under different simulation time horizons.